- IP to Startups
- Translational Sciences
Director of Molecular Design & Synthesis
Before arriving at Rutgers in 2012, David spent 20 years in the pharmaceutical/biotech industry in drug discovery medicinal chemistry. While at BMS, he made significant contributions to the discovery of saxagliptin (Onglyza), approved by the FDA in 2009 for the treatment of type II diabetes. David’s education includes a Ph.D. in synthetic organic chemistry from UC Irvine, and a NIH postdoctoral fellowship at Princeton University. Here at Rutgers, David and his team’s research interests focus on the design and synthesis of small molecule probes useful in the investigation of new biology, primarily focused on cancer, metabolic diseases and immunology.